首页> 美国卫生研究院文献>other >RANDOMIZED TRIAL OF PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) PLUS CARBOPLATIN VERSUS CARBOPLATIN IN PLATINUM-SENSITIVE (PS) PATIENTS WITH RECURRENT EPITHELIAL OVARIAN OR PERITONEAL CARCINOMA AFTER FAILURE OF INITIAL PLATINUM-BASED CHEMOTHERAPY (SOUTH WEST ONCOLOGY GROUP PROTOCOL S0200)

【2h】

RANDOMIZED TRIAL OF PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) PLUS CARBOPLATIN VERSUS CARBOPLATIN IN PLATINUM-SENSITIVE (PS) PATIENTS WITH RECURRENT EPITHELIAL OVARIAN OR PERITONEAL CARCINOMA AFTER FAILURE OF INITIAL PLATINUM-BASED CHEMOTHERAPY (SOUTH WEST ONCOLOGY GROUP PROTOCOL S0200)

机译：在华氏200度以上的初始白热病患者（最初的化疗）后复发性上皮性卵巢或腹膜癌的铂敏感性（PS）患者中聚脂脂质体阿霉素（PLD）加卡铂与卡铂的随机对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveBecause debate continues over the role of combination, platinum-based chemotherapy for platinum sensitive (PS), recurrent ovarian cancer (OC), we compared overall survival (OS), progression-free survival (PFS), confirmed complete response rate and time to treatment failure in this population.

机译：目的由于关于联合用药，铂类化学疗法对铂敏感（PS），复发性卵巢癌（OC）的作用的争论仍在继续，我们比较了总生存期（OS），无进展生存期（PFS），确定的完全缓解率和时间该人群的治疗失败。

著录项

期刊名称 other
作者
David S. Alberts; P. Y. Liu; Sharon P. Wilczynski; Mary C. Clouser; Ana Maria Lopez; David P. Michelin; Victor J. Lanzotti; Maurie Markman;
展开▼
作者单位

展开▼
年(卷),期 -1(108),1
年度 -1
页码 90–94
总页数 11
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献

1. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwes [J] . Alberts DS, Liu PY, Wilczynski SP, Gynecologic Oncology: An International Journal . 2008,第1期

机译：聚铂脂质体阿霉素（PLD）联合卡铂与卡铂在铂类初始化疗失败后对铂敏感性（PS）复发性上皮性卵巢或腹膜癌患者中的随机试验（Southwes
2. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An JNRG Oncology/Gynecologic Oncology Group study [J] . Landrum Lisa M., Brady William E., Armstrong Deborah K., Gynecologic Oncology: An International Journal . 2016,第2期

机译：聚乙二醇化脂质体阿霉素（PLD），卡铂，贝伐单抗和维利帕利在复发性，铂敏感性卵巢癌，原发性腹膜癌和输卵管癌的I期试验：JNRG肿瘤/妇科肿瘤小组研究
3. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. [J] . Markman M, Moon J, Wilczynski Gynecologic Oncology: An International Journal . 2010,第3期

机译：单药卡铂与卡铂加聚乙二醇化脂质体阿霉素治疗复发性卵巢癌：SWOG（S0200）3期随机试验的最终生存结果。
4. A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD) Carboplatin Bevacizumab and Veliparib in Recurrent Platinum-Sensitive Ovarian Primary Peritoneal and Fallopian Tube Cancer: An NRG Oncology/Gynecologic Oncology Group study [O] . Lisa M. Landrum, William E. Brady, Deborah K. Armstrong, -1

机译：聚乙二醇化脂质体阿霉素（PLD）卡铂贝伐单抗和维利帕利在复发性铂敏感性卵巢癌原发性腹膜癌和输卵管癌的I期试验：NRG肿瘤/妇科肿瘤小组研究
5. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study [O] . Lisa M. Landrum, William E. Brady, Deborah K. Armstrong, 2016

机译：经常性，铂敏感卵巢，原发性腹膜和输卵管癌症中的Pegymated脂质体Doxorubicin（PLD），卡铂，Bevacizumab和Veliparib的一期试验：NRG肿瘤学/妇科肿瘤组研究

RANDOMIZED TRIAL OF PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) PLUS CARBOPLATIN VERSUS CARBOPLATIN IN PLATINUM-SENSITIVE (PS) PATIENTS WITH RECURRENT EPITHELIAL OVARIAN OR PERITONEAL CARCINOMA AFTER FAILURE OF INITIAL PLATINUM-BASED CHEMOTHERAPY (SOUTH WEST ONCOLOGY GROUP PROTOCOL S0200)

摘要

著录项

相似文献

相关主题

期刊订阅